Boosted breast cancer treatment with cell membrane-coated PLGA nanocarriers: Investigating the interactions with various cell types.

Nanomaterials inspired by nature and applied in the medical field have exhibited remarkable potential to diagnose and treat diseases. However, further improvements are required to enhance therapeutic effectiveness, particularly in terms of targeting. In this study, we formulated paclitaxel (PTX)-loaded poly lactic-co-glycolic (PLGA) nanocarriers (PLGA-PTX NCs) and coated with cancer cell membrane derived from MCF-7 breast cancer cells, mPLGA-PTX NCs.

The amount of dextran in PLGA nanocarriers modulates protein corona and promotes cell membrane damage.

Polymeric nanocarriers (NCs) are efficient vehicles to prevent drug unspecific biodistribution and increase the drug amounts delivered to tumor tissues. However, some toxicological aspects of NCs still lack a comprehensive assessment, such as their effects on cellular processes that lead to toxicity. We evaluate the interaction of poly(lactic--glycolic acid) (PLGA) NCs prepared using dextran (Dex) and Pluronic®-F127 as stabilizing agents with myocardial cells (H9C2), breast adenocarcinoma cells (MCF-7) and macrophages (RAW 264.